06.25.08
DSM Biologics and Crucell have entered into an agreement with Avid Bioservices to bring Avid into their Vendor Network. Under the terms of the agreement, Avid will be a pre-approved CMO for licensees of the PER.C6 cell line in the western U.S. Avid is the first U.S.-based CMO to be awarded this status. Other terms of the agreement were not disclosed.
Karen King, president of DSM Biologics, noted, "We are confident that Avid's excellent reputation and service level will be instrumental in making the PER.C6 technology available to licensees on the west coast, bringing our technology to a wider regional base as we continue to grow globally."
Steven W. King, president of Avid Bioservices, added, "We are honored to achieve the distinction of being the first pre-approved U.S.-based CMO to manufacture proteins and antibodies using the PER.C6 cell line. This technology is recognized throughout our industry as providing important advantages compared to other platforms, including serum-free medium, scalability and high productivity levels, making the system an ideal fit for Avid."
The PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies.
Karen King, president of DSM Biologics, noted, "We are confident that Avid's excellent reputation and service level will be instrumental in making the PER.C6 technology available to licensees on the west coast, bringing our technology to a wider regional base as we continue to grow globally."
Steven W. King, president of Avid Bioservices, added, "We are honored to achieve the distinction of being the first pre-approved U.S.-based CMO to manufacture proteins and antibodies using the PER.C6 cell line. This technology is recognized throughout our industry as providing important advantages compared to other platforms, including serum-free medium, scalability and high productivity levels, making the system an ideal fit for Avid."
The PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies.